The Multidisciplinary Association for Psychedelic Studies (MAPS) and its Public Benefit Corp. arm, MAPS PBC, today published its second Phase 3 study (MAPP2) of MDMA-assisted therapy (MDMA-AT) for PTSD in the prestigious journal, Nature. In January 2023, MAPS announced that the study had been “successful”, confirming prior results. Now, the study’s published results show that the intervention…


Previous articleBetterLife Pharma to Host Investors Update Call on September 18, 2023
Next articleOptimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial